noscript

News and Announcements

Starpharma VP Dr Malcolm McColl appointed CEO of Viralytics

  • Published November 14, 2012 12:01PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

..During Dr McColl’s two years at Starpharma he was a driver of partnering transactions and had a lead role in the in-house docetaxel oncology drug program
..Big pharma experience and completed approximately 50 research, development, licensing, M&A and other partnering deals
..Considerable global experience and strong international networks

Starpharma Vice President and respected biotechnology professional Dr Malcolm McColl has been appointed Chief Executive Officer of Viralytics Limited (ASX:VLA).

From 2010 Dr McColl was Vice-President of Business Development at Starpharma where he was responsible for completion of partnering transactions with global and regional companies. He initiated and had a lead role in the development of Starpharma’s in-house docetaxel oncology drug program.

Prior to returning home to Australia in 2010 Dr McColl spent three years based in the UK at NYSE-listed global healthcare company Hospira as Business Development Director for Europe, Middle East and Africa. In that time he led negotiations and due diligence for a significant number of licensing and acquisition transactions with a focus on oncology.

Prior to this role he was Director of Business Development for the Asia Pacific region at Hospira (previously Mayne Pharma) and also 13 years with CSL in roles in its Animal Health Division including four years based in the USA as Global Vice-President Business Development.

Announcing the changes, VLA’s Executive Chairman Paul Hopper said he is delighted to appoint someone of Dr McColl’s calibre to lead the Viralytics team.

“Dr McColl’s experience with big pharmaceutical companies such as CSL and Hospira and proven ability to negotiate at the highest level is ideal for Viralytics,” Mr Hopper said.

“Viralytics is at an important stage in its development and we’re determined to do everything we can to maximise value for shareholders. Every good Chairman knows that a strong CEO appointment is essential in enabling the value inflexions.”

Dr McColl brings more than 20 years biotechnology experience to the position. He has spent most of this time developing or acquiring new products and maximising commercial returns by way of partnerships with global and local pharmaceutical companies. He has completed approximately 50 research, development, licensing, M&A and other partnering transactions in his career.

Dr McColl said, “The Viralytics platform has enormous scope and using oncolytic virotherapy to treat cancer is emerging as a compelling new technology in cancer research and treatment. Viralytics is well-respected with excellent programs already in place thanks to the good work of current and previous management. I look forward to making a substantial contribution to the future success of Viralytics and driving the programs forward.”

Dr McColl has a Bachelor of Veterinary Science degree with first class honours from the University of Melbourne and an MBA from the Melbourne Business School.

Enquiries
Paul Hopper                                                 Rudi Michelson
Executive Chairman                                     Monsoon Communications
Aust Mbl: 0406 671 515                               03 9620 3333
US Mbl: +1 8583345820
[email protected]
www.viralytics.com

 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now